Literature DB >> 23856800

Chondrolysis of the hip in an adolescent: clinical and radiological outcomes.

Ana Paula Sakamoto1, Larissa Lucati Ramos, Artur da Rocha Corrêa Fernandes, Maria Teresa Terreri.   

Abstract

Idiopathic chondrolysis of the hip is a rare condition of unknown etiology characterized by progressive destruction of the hyaline cartilage that covers the femoral head and acetabulum. Idiopathic chondrolysis of the hip has an insidious beginning and affects more often female adolescents. Patients report severe hip pain, mobility limitation, and even claudication. This study aimed at reporting one case of that rare disease: an 11-year-old female adolescent with chondrolysis, followed up for three years. Inflammatory activity tests were normal. Imaging tests (radiography, ultrasonography and magnetic resonance) were essential for the diagnosis. The treatment was based on pain control and preservation of the joint mobility, and included low-impact physical activity, non-steroidal anti-inflammatory drugs, and disease-modifying antirheumatic drugs, with good response after 12 months of treatment. Surgery was not necessary. 2013 Elsevier Editora Ltda. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23856800

Source DB:  PubMed          Journal:  Rev Bras Reumatol        ISSN: 0482-5004


  2 in total

Review 1.  Idiopathic hip chondrolysis: a case report of a Caucasian HLA-B27 positive adolescent with a history of long walking.

Authors:  Khaled T Kampani; Dimitrios V Papadopoulos; Andreas G Tsantes; Anna Batistatou; Aristotelis Fylaktos; Christos D Papageorgiou
Journal:  Rheumatol Int       Date:  2019-01-05       Impact factor: 2.631

Review 2.  MRI Features and Treatment for Idiopathic Chondrolysis of the Hip (ICH) in Children: Outcomes of a Systematic Review.

Authors:  Sandeep Kumar Nema; Premkumar Ramasubramani; Jose Austine; Govind Karunakaran; Vendoti Nitheesha Reddy; Vendoti Midhusha Reddy
Journal:  Indian J Orthop       Date:  2022-07-02       Impact factor: 1.033

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.